Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 4/20 | 0.49 |
| ▸ | PMM2 | O15305 | 1/20 | 0.49 |
| ▸ | MPI | P34949 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | PHOSPHO1 | Q8TCT1 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | HTR7 | P34969 | 1/20 | 0.48 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5743752 | 0.86 | ALDH1A1 (0.66) | GAATP53MAPTPKMALOX15 | |
| SCHEMBL4203044 | 0.85 | ALDH1A1 (0.64) | GAATP53MAPTPKMALOX15 | |
| SCHEMBL14562466 | 0.85 | GAA (0.57) | GAATP53MAPTPKMALOX15 | |
| SCHEMBL29641479 | 0.85 | GAA (0.57) | GAATP53MAPTPKMALOX15 | |
| SCHEMBL1490676 | 0.84 | PLOD2 (0.60) | GAATP53NPC1HPGDALDH1A1 | |
| SCHEMBL4250883 | 0.82 | KMO (0.68) | GAATP53MAPTPKMALOX15 | |
| SCHEMBL2876503 | 0.82 | ADRB1 (0.59) | GAATP53MAPTPKMALOX15 | |
| SCHEMBL14696856 | 0.82 | ALDH1A1 (0.71) | GAATP53MAPTPKMALOX15 | |
| SCHEMBL28167772 | 0.81 | KMT2A (0.73) | GAAMAPTALOX15HPGDALDH1A1 | |
| SCHEMBL1359510 | 0.81 | ALDH1A1 (0.65) | GAAMAPTALOX15NPC1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107108610-B | Novel tetrahydropyridopyrimidine and tetrahydropyridopyridine compounds for the treatment and prophylaxis of hepatitis B virus infections | 豪夫迈·罗氏有限公司 | 2019-06-04 | — | — | CN | disclosed |
| US-20180036317-A1 | METHOD OF TREATING CONDITIONS WITH KINASE INHIBITORS | ALLERGAN INC (US) | 2018-02-08 | — | — | US | disclosed |
| US-20180036317-A1 | METHOD OF TREATING CONDITIONS WITH KINASE INHIBITORS | ALLERGAN INC (US) | 2018-02-08 | — | — | US | disclosed |
| US-20180036317-A1 | METHOD OF TREATING CONDITIONS WITH KINASE INHIBITORS | ALLERGAN INC (US) | 2018-02-08 | — | — | US | disclosed |
| CN-107624113-A | Tetrahydropyridopyrimidines and tetrahydropyridopyridines as inhibitors of HBsAg (HBV surface antigen) and HBV DNA production for the treatment of hepatitis B virus infection | 豪夫迈·罗氏有限公司 | 2018-01-23 | — | — | CN | disclosed |
| US-9820989-B2 | Method of treating conditions with kinase inhibitors | ALLERGAN, INC. (US) | 2017-11-21 | — | — | US | disclosed |
| US-9820989-B2 | Method of treating conditions with kinase inhibitors | ALLERGAN, INC. (US) | 2017-11-21 | — | — | US | disclosed |
| US-9820989-B2 | Method of treating conditions with kinase inhibitors | ALLERGAN, INC. (US) | 2017-11-21 | — | — | US | disclosed |
| CN-107108610-A | Novel tetrahydropyridopyrimidine and tetrahydropyridopyridine compounds for the treatment and prophylaxis of hepatitis B virus infections | 豪夫迈·罗氏有限公司 | 2017-08-29 | — | — | CN | disclosed |
| US-20170143728-A1 | METHOD OF TREATING CONDITIONS WITH KINASE INHIBITORS | ALLERGAN, INC. | 2017-05-25 | — | — | US | disclosed |
| US-20130237537-A1 | METHOD OF TREATING CONDITIIONS WITH KINASE INHIBITORS | ALLERGAN, INC. (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130237538-A1 | KINASE INHIBITORS | ALLERGAN, INC. (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130237538-A1 | KINASE INHIBITORS | ALLERGAN, INC. (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130237537-A1 | METHOD OF TREATING CONDITIIONS WITH KINASE INHIBITORS | ALLERGAN, INC. (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130237537-A1 | METHOD OF TREATING CONDITIIONS WITH KINASE INHIBITORS | ALLERGAN, INC. (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130237538-A1 | KINASE INHIBITORS | ALLERGAN, INC. (US) | 2013-09-12 | — | — | US | disclosed |
| US-20120183498-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES | NITZ THEODORE J (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120183498-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES | NITZ THEODORE J (US) | 2012-07-19 | — | — | US | disclosed |
| US-8202896-B2 | Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases | MICRODOSE THERAPEUTX, INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-8202896-B2 | Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases | MICRODOSE THERAPEUTX, INC. (US) | 2012-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180036317-A1 | METHOD OF TREATING CONDITIONS WITH KINASE INHIBITORS | MAP3K1, MAPK1, MAP3K2 | GAA 1198/4885TP53 2392/4885MAPT 2008/4885 |
| US-20120183498-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES | TTPA, HAVCR2, ZC3HAV1 | GAA 1572/4885TP53 770/4885MAPT 2383/4885 |
| US-20170143728-A1 | METHOD OF TREATING CONDITIONS WITH KINASE INHIBITORS | MAP3K1, MAPK1, MAP3K2 | GAA 1198/4885TP53 2392/4885MAPT 2008/4885 |
| US-20130237537-A1 | METHOD OF TREATING CONDITIIONS WITH KINASE INHIBITORS | CDK5, MAP3K1, ALDH1A2 | GAA 508/4885TP53 1778/4885MAPT 2168/4885 |
| US-20130237538-A1 | KINASE INHIBITORS | MAP3K1, MAP3K6, MAP3K2 | GAA 2053/4885TP53 376/4885MAPT 3468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.